Literature DB >> 20442350

Adverse drug reactions in hospital and ambulatory care settings identified using a large administrative database.

Sandra L Kane-Gill1, Jill Van Den Bos, Steven M Handler.   

Abstract

BACKGROUND: Previous studies are limited in sample size and number of sites for the detection and characterization of adverse drug reactions (ADRs) in ambulatory care and hospital settings.
OBJECTIVE: To determine the prevalence and distribution of suspected ADRs according to demographic characteristics and drug classes for ambulatory care and hospitalized patients.
METHODS: A cross-sectional evaluation of administrative data from 2002-2005, containing a maximum of 20 million Medicare and commercially insured patients in a year, was completed. Individuals with one or more claims suggesting an ADR were identified, using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) criteria referred to as a "suspected ADR." Frequency of ICD-9-CM codes consistent with suspected ADRs for the 4 years was calculated for hospital and ambulatory care settings, based on age ranges, comorbidities, and drug classes.
RESULTS: Between 2002 and 2005, the average annual prevalence of suspected ADRs was 0.5%, with a total of 249,633 suspected ADRs during the 4 years. The mean age of hospitalized patients experiencing a suspected ADR was 12 years older than that of ambulatory care patients and 20 years older than that of the general database population. Diseases of the circulatory and endocrine/nutritional/metabolic systems rank among the top 5 comorbid conditions in hospitalized patients who had a suspected ADR. Injury and poisoning was the primary comorbidity in ambulatory patients. High-risk medications frequently associated with suspected ADRs in both settings were antineoplastic and anticoagulant agents. Other drug classes commonly associated with suspected ADRs in hospitalized patients were antihypertensives and diuretics. For the ambulatory care setting, drug classes frequently associated with suspected ADRs were antirheumatic and antiarteriosclerotic agents.
CONCLUSIONS: ADR detection, using administrative data, revealed differences in age, comorbidities, and drug classifications between ambulatory care and hospital settings. The results can be used to develop focused prevention strategies and targeted surveillance for individuals most at risk for developing ADRs.

Entities:  

Mesh:

Year:  2010        PMID: 20442350     DOI: 10.1345/aph.1M726

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  11 in total

1.  Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions.

Authors:  Casey Lynnette Overby; Emily Beth Devine; Peter Tarczy-Hornoch; Ira J Kalet
Journal:  J Am Med Inform Assoc       Date:  2012-04-26       Impact factor: 4.497

2.  Significant events.

Authors:  David Jewell
Journal:  Br J Gen Pract       Date:  2011-06       Impact factor: 5.386

Review 3.  Intensive insulin therapy in critically ill hospitalized patients: making it safe and effective.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

4.  A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUs.

Authors:  Pamela L Smithburger; Mitchell S Buckley; Mark A Culver; Sarah Sokol; Ishaq Lat; Steven M Handler; Levent Kirisci; Sandra L Kane-Gill
Journal:  Crit Care Med       Date:  2015-08       Impact factor: 7.598

5.  Analysis of risk factors for adverse drug events in critically ill patients*.

Authors:  Sandra L Kane-Gill; Levent Kirisci; Margaret M Verrico; Jeffrey M Rothschild
Journal:  Crit Care Med       Date:  2012-03       Impact factor: 7.598

6.  Hospitalizations and deaths related to adverse drug events worldwide: Systematic review of studies with national coverage.

Authors:  Lunara Teles Silva; Ana Carolina Figueiredo Modesto; Rita Goreti Amaral; Flavio Marques Lopes
Journal:  Eur J Clin Pharmacol       Date:  2021-10-30       Impact factor: 2.953

7.  Anticoagulants' Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study.

Authors:  Paul Frappé; Joël Cogneau; Yoann Gaboreau; Nathan Abenhaïm; Marc Bayen; Claude Guichard; Jean-Pierre Jacquet; François Lacoin; Sandra Liébart; Laurent Bertoletti; Jean-Luc Bosson
Journal:  Ann Fam Med       Date:  2020-03       Impact factor: 5.166

8.  Allergic Reactions Captured by Voluntary Reporting.

Authors:  Kimberly G Blumenthal; Anna R Wolfson; Yu Li; Claire M Seguin; Neelam A Phadke; Aleena Banerji; Elizabeth Mort
Journal:  J Patient Saf       Date:  2021-12-01       Impact factor: 2.844

9.  Areas of improvement in anticoagulant safety. Data from the CACAO study, a cohort in general practice.

Authors:  Paul Frappé; Joël Cogneau; Yoann Gaboreau; Nathan Abenhaïm; Marc Bayen; Matthieu Calafiore; Claude Guichard; Jean-Pierre Jacquet; François Lacoin; Laurent Bertoletti
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

10.  Development and Validation of a Deep Learning Model for Detection of Allergic Reactions Using Safety Event Reports Across Hospitals.

Authors:  Jie Yang; Liqin Wang; Neelam A Phadke; Paige G Wickner; Christian M Mancini; Kimberly G Blumenthal; Li Zhou
Journal:  JAMA Netw Open       Date:  2020-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.